AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35106694 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐IVF treatments
Number of subjects: 251
Study 33607321 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality criteria for randomized controlled trials as listed in author guidelines
Number of subjects: 0
Study 33607321 — intervention group
Group type: COMPARATOR
Intervention: Submission software requirements
Number of subjects: 0
Study 33607321 — intervention group
Group type: COMPARATOR
Intervention: Comparison between top medical journals and other obstetrics and gynecology journals
Number of subjects: 0
Study 33607321 — intervention group
Group type: COMPARATOR
Intervention: Comparison among top vs other obstetrics and gynecology journals
Number of subjects: 0
Study 35708047 — intervention group
Group type: EXPERIMENTAL
Intervention: Exoskeleton exercise (Exo)
Number of subjects: 40
Study 35708047 — intervention group
Group type: COMPARATOR
Intervention: No exoskeleton exercise (Nxo)
Number of subjects: 40
Study 35708047 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (Con)
Number of subjects: 40
Study 34738828 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure plug-based technique (MANTA, Teleflex)
Number of subjects: 516
Study 34738828 — intervention group
Group type: COMPARATOR
Intervention: Primary suture-based technique (ProGlide, Abbott Vascular)
Number of subjects: 516
Study 33693537 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care control (PO-10, rifampicin 10 mg/kg/day)
Number of subjects: 61
Study 33693537 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous rifampicin (IV-20, 20 mg/kg/day)
Number of subjects: 61
Study 33693537 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral rifampicin (PO-35, 35 mg/kg/day)
Number of subjects: 61
Study 32886121 — intervention group
Group type: EXPERIMENTAL
Intervention: Reports containing age-appropriate prevalence data for common imaging findings in individuals without back pain (intervention group)
Number of subjects: 250401
Study 32886121 — intervention group
Group type: COMPARATOR
Intervention: Standard lumbar spine imaging reports (control group)
Number of subjects: 250401
Study 35977831 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering (systolic ≤ 125 mm Hg)
Number of subjects: 82
Study 35977831 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure lowering (systolic 130‐140 mm Hg)
Number of subjects: 82
Study 34424565 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 126
Study 35115450 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV hyperimmune globulin
Number of subjects: 344
Study 35115450 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 344
Study 33152333 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine-sulfate (HCQS)
Number of subjects: 0
Study 33549194 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole (300 mg twice on day 1, followed by 300 mg once a day for days 2–84)
Number of subjects: 575
Study 33549194 — intervention group
Group type: COMPARATOR
Intervention: Voriconazole (6 mg/kg intravenous or 300 mg oral twice on day 1 followed by 4 mg/kg intravenously or 200 mg orally twice a day for days 2–84)
Number of subjects: 575
Study 33549194 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole
Number of subjects: 575
Study 33549194 — intervention group
Group type: COMPARATOR
Intervention: Voriconazole
Number of subjects: 575
Study 33101762 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing the writing process vs. only rating spiral/writing photos
Number of subjects: 0
Study 33101762 — intervention group
Group type: EXPERIMENTAL
Intervention: Rating each arm individually vs. concurrently
Number of subjects: 0
Study 33101762 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine vs. sitting position for heal to shin scores
Number of subjects: 0
Study 33101762 — intervention group
Group type: EXPERIMENTAL
Intervention: Cursive writing vs. script writing
Number of subjects: 0
Study 36289083 — intervention group
Group type: EXPERIMENTAL
Intervention: Touch Surgery™ (TS)
Number of subjects: 40
Study 36289083 — intervention group
Group type: COMPARATOR
Intervention: Virtual Reality (VR) trainer
Number of subjects: 40
Study 34564985 — intervention group
Group type: EXPERIMENTAL
Intervention: NACT combined with laparoscopic cytoreductive surgery
Number of subjects: 116
Study 34564985 — intervention group
Group type: COMPARATOR
Intervention: Control group (cytoreductive surgery alone)
Number of subjects: 116
Study 32135507 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial source tracking (MST) assays
Number of subjects: 94
Study 32135507 — intervention group
Group type: EXPERIMENTAL
Intervention: Soil samples
Number of subjects: 94
Study 32135507 — intervention group
Group type: EXPERIMENTAL
Intervention: Stored water samples
Number of subjects: 94
Study 32135507 — intervention group
Group type: EXPERIMENTAL
Intervention: Source water and food surfaces
Number of subjects: 94
Study 32135507 — intervention group
Group type: EXPERIMENTAL
Intervention: Avian target GFD
Number of subjects: 94
Study 32135507 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian censored regression and Bayesian logistic regression
Number of subjects: 94
Study 32135507 — intervention group
Group type: EXPERIMENTAL
Intervention: Water storage container characteristics
Number of subjects: 94
Study 35412627 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial prophylaxis discontinued within 24 hours after surgery (group 24)
Number of subjects: 1211
Study 35412627 — intervention group
Group type: COMPARATOR
Intervention: Antimicrobial prophylaxis discontinued 24 to 48 hours after surgery (group 48)
Number of subjects: 1211
Study 33499139 — intervention group
Group type: EXPERIMENTAL
Intervention: Maqui-citrus beverage with stevia
Number of subjects: 138
Study 33499139 — intervention group
Group type: EXPERIMENTAL
Intervention: Maqui-citrus beverage with sucralose
Number of subjects: 138
Study 33499139 — intervention group
Group type: COMPARATOR
Intervention: Maqui-citrus beverage with sucrose
Number of subjects: 138
Study 32833063 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 0
Study 32833063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33046145 — intervention group
Group type: EXPERIMENTAL
Intervention: Probands with ADHD
Number of subjects: 159
Study 33046145 — intervention group
Group type: EXPERIMENTAL
Intervention: Unaffected siblings
Number of subjects: 159
Study 33046145 — intervention group
Group type: COMPARATOR
Intervention: Typically developing controls
Number of subjects: 159
Study 34488846 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/kg PZQ at baseline and placebo at 6 months
Number of subjects: 600
Study 34488846 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/kg PZQ at baseline and 40 mg/kg PZQ at 6 months
Number of subjects: 600
Study 34488846 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg/kg PZQ at baseline and placebo at 6 months
Number of subjects: 600
Study 34488846 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg/kg PZQ at baseline and 80 mg/kg PZQ at 6 months
Number of subjects: 600
Study 33369355 — intervention group
Group type: EXPERIMENTAL
Intervention: CC-486 (300 mg) once daily for 14 days per 28-day cycle
Number of subjects: 472
Study 33369355 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for 14 days per 28-day cycle
Number of subjects: 472
Study 35783319 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based parenting intervention
Number of subjects: 785
Study 35783319 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 785
Study 32000812 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR-based intervention
Number of subjects: 6000
Study 32000812 — intervention group
Group type: EXPERIMENTAL
Intervention: Text Messaging (TM)
Number of subjects: 6000
Study 32000812 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone coaching
Number of subjects: 6000
Study 32000812 — intervention group
Group type: COMPARATOR
Intervention: Continued EHR
Number of subjects: 6000
Study 32000812 — intervention group
Group type: COMPARATOR
Intervention: Continued TM
Number of subjects: 6000
Study 35183780 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 µm of Rose Bengal (RB)
Number of subjects: 20
Study 35183780 — intervention group
Group type: EXPERIMENTAL
Intervention: Neem extract
Number of subjects: 20
Study 35183780 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea tree oil (TTO)
Number of subjects: 20
Study 35183780 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% CHX solutions
Number of subjects: 20
Study 35183780 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study 33761442 — intervention group
Group type: EXPERIMENTAL
Intervention: Health facilities (HFs) contacted by BMS company representatives
Number of subjects: 0
Study 33761442 — intervention group
Group type: EXPERIMENTAL
Intervention: Health personnel knowledge of the WHO Code
Number of subjects: 0
Study 33761442 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice received by mothers on feeding their children BMS
Number of subjects: 0
Study 33761442 — intervention group
Group type: EXPERIMENTAL
Intervention: Points of sale (POS) compliance with the WHO Code
Number of subjects: 0
Study 33761442 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS labels compliance with the WHO Code
Number of subjects: 0
Study 33761442 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS advertising expenses in the media
Number of subjects: 0
Study 35247444 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.5%‐isomaltulose
Number of subjects: 13
Study 35247444 — intervention group
Group type: COMPARATOR
Intervention: 6.5%‐sucrose
Number of subjects: 13
Study 35247444 — intervention group
Group type: COMPARATOR
Intervention: water
Number of subjects: 13
Study 34600585 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftolozane/tazobactam (C/T) 3g every 8 hours
Number of subjects: 459
Study 34600585 — intervention group
Group type: COMPARATOR
Intervention: Meropenem 1g every 8 hours
Number of subjects: 459
Study 32750572 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily symptom check-in text messages, plus medication reminder or inspirational quote text
Number of subjects: 40
Study 32750572 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 40
Study 35795313 — intervention group
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC) 900 mg twice daily for 3 months
Number of subjects: 100
Study 35795313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 33721560 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg IV every 3 weeks for 16 cycles or up to 1 year
Number of subjects: 809
Study 33721560 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 809
Study 33721560 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 809
Study 35678894 — intervention group
Group type: EXPERIMENTAL
Intervention: CIU‐SP (intraureteral stent placement)
Number of subjects: 91
Study 34622679 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT with cilostazol and clopidogrel or aspirin
Number of subjects: 547
Study 34622679 — intervention group
Group type: COMPARATOR
Intervention: SAPT with clopidogrel or aspirin
Number of subjects: 547
Study 32293706 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitolisant hydrochloride (40 mg)
Number of subjects: 6
Study 35501349 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% atropine
Number of subjects: 43
Study 35501349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 32745891 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin 20 IU
Number of subjects: 97
Study 32745891 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin 40 IU
Number of subjects: 97
Study 32745891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 32745891 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (both doses)
Number of subjects: 97
Study 32945015 — intervention group
Group type: EXPERIMENTAL
Intervention: Toric contact lenses
Number of subjects: 34
Study 32945015 — intervention group
Group type: COMPARATOR
Intervention: Spherical equivalent contact lenses
Number of subjects: 34
Study 34653740 — intervention group
Group type: EXPERIMENTAL
Intervention: Real intermittent theta burst stimulation (iTBS) targeting the cerebellar vermis area VII-B, 100% active motor threshold, two sessions/day for five days (total = 6000 pulses)
Number of subjects: 60
Study 34653740 — intervention group
Group type: COMPARATOR
Intervention: Sham intermittent theta burst stimulation (iTBS)
Number of subjects: 60
Study 33314397 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 33
Study 33314397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 37277072 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexpramipexole 150 mg BID
Number of subjects: 103
Study 37277072 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexpramipexole 75 mg BID
Number of subjects: 103
Study 37277072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 34836388 — intervention group
Group type: EXPERIMENTAL
Intervention: Biobran/MGN-3 (500 mg/day)
Number of subjects: 80
Study 34836388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 32635352 — intervention group
Group type: COMPARATOR
Intervention: Pedelec use (P)
Number of subjects: 101
Study 35156616 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 0
Study 35156616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35156616 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 0
Study 33517607 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC)
Number of subjects: 100
Study 33517607 — intervention group
Group type: COMPARATOR
Intervention: Standard oxygen treatment (venturi mask/nasal cannula)
Number of subjects: 100
Study 32598165 — intervention group
Group type: EXPERIMENTAL
Intervention: Iowa Infant Feeding Attitudes Scale (IIFAS)
Number of subjects: 164
Study 32598165 — intervention group
Group type: EXPERIMENTAL
Intervention: Baby Eating Behavior Questionnaire (BEBQ)
Number of subjects: 164
Study 32598165 — intervention group
Group type: EXPERIMENTAL
Intervention: General appetite score for Russian infants
Number of subjects: 164
Study 32598165 — intervention group
Group type: EXPERIMENTAL
Intervention: Satiety responsiveness score for Russian infants
Number of subjects: 164
Study 32598165 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement with IIFAS statement 'Formula feeding is more convenient than breastfeeding'
Number of subjects: 164
Study 36288939 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 400 µg three times a day for seven days
Number of subjects: 42
Study 36288939 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 42
Study 36288939 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide
Number of subjects: 42
Study 33085032 — intervention group
Group type: EXPERIMENTAL
Intervention: palbociclib plus letrozole
Number of subjects: 81
Study 33085032 — intervention group
Group type: COMPARATOR
Intervention: placebo plus letrozole
Number of subjects: 81
Study 33085032 — intervention group
Group type: EXPERIMENTAL
Intervention: palbociclib plus fulvestrant
Number of subjects: 81
Study 33085032 — intervention group
Group type: COMPARATOR
Intervention: placebo plus fulvestrant
Number of subjects: 81
Study 33085032 — intervention group
Group type: EXPERIMENTAL
Intervention: palbociclib
Number of subjects: 81
Study 33085032 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 81
Study 35791768 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative SpO2 ≤ 94%
Number of subjects: 45
Study 35791768 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative FVC ≤ 50%
Number of subjects: 45
Study 35791768 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative SpO2
Number of subjects: 45
Study 35791768 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative FVC
Number of subjects: 45
Study 35791768 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative poorly aerated lung volume
Number of subjects: 45
Study 32439849 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine intake
Number of subjects: 0
Study 32439849 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise
Number of subjects: 0
Study 32439849 — intervention group
Group type: COMPARATOR
Intervention: Light intensity exercise
Number of subjects: 0
Study 32439849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32439849 — intervention group
Group type: COMPARATOR
Intervention: No ingestion
Number of subjects: 0
Study 35436957 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive education program on treatment of tobacco-use disorder
Number of subjects: 86
Study 35436957 — intervention group
Group type: COMPARATOR
Intervention: Short didactic session on a non-tobacco-related topic (Control)
Number of subjects: 86
Study 34385707 — intervention group
Group type: EXPERIMENTAL
Intervention: gosuranemab
Number of subjects: 486
Study 34385707 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 486
Study 33030598 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised aerobic endurance, resistance, and balance exercises twice a week at the hospital plus home-based exercise once a week for 12-24 weeks
Number of subjects: 30
Study 34747972 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention promoting healthy diet and physical activity, engaging schools and families, with the assistance of a smartphone app.
Number of subjects: 1392
Study 34747972 — intervention group
Group type: COMPARATOR
Intervention: Control group engaged in usual practices.
Number of subjects: 1392
Study 34747972 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention
Number of subjects: 1392
Study 34047915 — intervention group
Group type: EXPERIMENTAL
Intervention: Mohs micrographic surgery (MMS)
Number of subjects: 31
Study 34047915 — intervention group
Group type: EXPERIMENTAL
Intervention: Staged excision (SE)
Number of subjects: 31
Study 32682770 — intervention group
Group type: EXPERIMENTAL
Intervention: Home mechanical ventilation (HMV) initiation
Number of subjects: 96
Study 32682770 — intervention group
Group type: COMPARATOR
Intervention: In-hospital mechanical ventilation (HMV) initiation
Number of subjects: 96
Study 36195326 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided radiofrequency ablation (RFA)
Number of subjects: 1279
Study 35768989 — intervention group
Group type: EXPERIMENTAL
Intervention: ESI with betamethasone (ESI‐beta)
Number of subjects: 600
Study 35768989 — intervention group
Group type: EXPERIMENTAL
Intervention: ESI with dexamethasone (ESI‐dexa)
Number of subjects: 600
Study 33347003 — intervention group
Group type: EXPERIMENTAL
Intervention: VYC‐20L
Number of subjects: 192
Study 33347003 — intervention group
Group type: COMPARATOR
Intervention: Control (6 months later)
Number of subjects: 192
Study 34353046 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU nursing risk management combined with the cluster nursing model
Number of subjects: 110
Study 34353046 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing
Number of subjects: 110
Study 32362552 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg bevacizumab
Number of subjects: 170
Study 32362552 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg ranibizumab
Number of subjects: 170
Study 32362552 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg bevacizumab (subgroup with BCVA ≤69 letters)
Number of subjects: 170
Study 32362552 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg ranibizumab (subgroup with BCVA ≤69 letters)
Number of subjects: 170
Study 32362552 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg bevacizumab (subgroup with BCVA ≥70 letters)
Number of subjects: 170
Study 32362552 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg ranibizumab (subgroup with BCVA ≥70 letters)
Number of subjects: 170
Study 35797047 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 270
Study 35797047 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (SA)
Number of subjects: 270
Study 35797047 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care only)
Number of subjects: 270
Study 33506973 — intervention group
Group type: EXPERIMENTAL
Intervention: Health professional-led functional exercise programme (n = 78), performed up to four times a day, 7 days a week for 2 weeks, in addition to usual care.
Number of subjects: 140
Study 33506973 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone (n = 62).
Number of subjects: 140
Study 32404854 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hepatectomy (LH)
Number of subjects: 160
Study 32404854 — intervention group
Group type: COMPARATOR
Intervention: Open hepatectomy (OH)
Number of subjects: 160
Study 35700977 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted exercise and education curriculum (Fit & Strong!)
Number of subjects: 0
Study 33668564 — intervention group
Group type: EXPERIMENTAL
Intervention: EGF-containing ointment
Number of subjects: 0
Study 33668564 — intervention group
Group type: COMPARATOR
Intervention: Petrolatum (Control)
Number of subjects: 0
Study 32594785 — intervention group
Group type: EXPERIMENTAL
Intervention: BAC-preserved timolol
Number of subjects: 85
Study 32594785 — intervention group
Group type: EXPERIMENTAL
Intervention: BAC-preserved brimonidine
Number of subjects: 85
Study 32594785 — intervention group
Group type: COMPARATOR
Intervention: Preservative-free timolol
Number of subjects: 85
Study 32594785 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medications)
Number of subjects: 85
Study 36154487 — intervention group
Group type: EXPERIMENTAL
Intervention: Dramatic narrative featuring Latina characters countering prevalent myths about COVID-19 vaccines
Number of subjects: 390
Study 36154487 — intervention group
Group type: COMPARATOR
Intervention: Nonnarrative control film containing similar information
Number of subjects: 390
Study 32089450 — intervention group
Group type: EXPERIMENTAL
Intervention: cVEMP test
Number of subjects: 22
Study 32089450 — intervention group
Group type: EXPERIMENTAL
Intervention: oVEMP test
Number of subjects: 22
Study 32089450 — intervention group
Group type: EXPERIMENTAL
Intervention: caloric test
Number of subjects: 22